Over the last 30 years, NHL in children has progressed from an aggressive lethal cancer to better characterized lymphomas with specific, more successful treatments. Discovery of oncogenic pathways and improved classification have led to directly to improved outcomes. However, the toxicity of therapy is significant, outcome for relapsed disease generally poor, and there has been a slowing of the progress towards 100% cure. Fortunately, we are entering an exciting time in the treatment of pediatric NHL where novel therapies may soon radically change the treatment paradigm for this disease and hopefully lead to less toxicity and improved outcomes. This presentation provided an overview of some of the challenges faced in the treatment of pediatric NHL and how novel therapies may overcome them.
Eric Lowe, MD
Director, Pediatric Oncology Division, Pediatric Hematology/Oncology
Children’s Hospital of the King’s Daughters, Norfolk, Virginia